



Cohance Lifesciences:
A Global CDMO Platform Trusted by
19 of the Top 20 Pharma Innovators

Cohance Lifesciences delivers integrated CDMO solutions for global innovators
—backed by robust chemistry expertise, regulatory compliance, and scalable infrastructure.



Small Molecule APIs



Antibody-Drug
Conjugates (ADCs)



Nucleic Acid
Chemistry

Proven Strength in APIs, Intermediates & Starting Materials: From Early Phase to Global Commercial GMP Supply

Small Molecule Capabilities

Process Development

Route scouting & identification;
phase-appropriate process
development with DoE,
impurity profiling, and scalable
optimization.

Analytical Development

Phase-appropriate analytical
methods, impurity isolation
and characterization, stability
studies for secure scale-up.

Scale-up and Commercial Production

Grams to multi-ton capacity
across USFDA, EMA, PMDA
audited sites with validated
processes and traceability.

Lifecycle Manufacturing

Process improvement, cost
optimization, reprocessing,
impurity purge, and green
practices.

Regulatory Documentation

Support for IND, IMPD, DMF
submissions across USFDA,
EMA, PMDA markets.

Why Cohance for Small Molecule APIs

34+ years of
CDMO expertise

Complex chemistries,
HPAPIs (OEB Level 6)

Flow chemistry
capabilities (PFRs,
photo flow, CSTRs)

Advanced bromine
and cyanide handling
systems

250+ chemistries, 350+
routes, 30+ reaction
classes mastered

Multi-site USFDA/
EDQM certified
facilities

Backward-integrated
supply chain





Seamless, integrated chemistry services in ADC development from Discovery to Commercial



Integrated CRDMO Capabilities

Discovery, IND enabling, and GMP Bioconjugation up to Phase II

Analytical method development & regulatory documentation

Industry-standard & custom linkers

Custom payloads and linkers

Camptothecin & Auristatin derivative synthesis

Why Cohance + NJ Bio for ADCs

Deep expertise in ADC domain, with integrated knowledge spanning chemistry, biology, and manufacturing

Global leading commercial supplier of S-Trione and SN-38

High Potency handling
 $OEL < 10 \text{ ng/m}^3$

USFDA and EDQM approved facility for HPAPI and Payload-Linker manufacturing

Robust Backward Integration for consistent supply of key starting materials (KSMs), including S-Trione, Tetralone derivative (CAS# 182182-31-6) & others

Driving innovation in Nucleic Acid Chemistry: Discovery to Commercial with GMP manufacturing capabilities



Capabilities

Custom Synthesis -

Proprietary and modified nucleoside derivatives, GalNAc conjugates, NTPs, CAP reagents, fluorescent dyes.

Process Development & Scale-up -

From milligrams to 100+ kg GMP production.

Analytical & Regulatory Support -

Method development, impurity profiling, IND-enabling documentation.

Flexible Engagement Models -

Fixed-scope or FTE-based, from early development to commercial readiness.

Product Categories

Drug Delivery Compounds (GalNAc)

Modified Phosphoramidites

CAP Reagents

Fluorescent Dyes and Linkers

Bridged Nucleic Acids (BNA)

Nucleoside Triphosphates (NTPs)

Blockmers

Why Cohance + Sapala for Nucleic Acid Chemistry

Only Indian CDMO with dedicated infrastructure for oligonucleotide intermediates & deep nucleic acid scale-up capabilities

cGMP facility in Hyderabad with 700 kg annual capacity for oligonucleotide building blocks

ISO Class 8 / Grade D Cleanrooms with HEPA filtration and RH control for sensitive drying and dispensing

Versatile Reactor Suite: 10+ reactors (glass, stainless steel, Hastelloy) ranging from 50L to 1,000L





Cohance at a Glance

34 ⁺	19	15 ⁺	1,000 ⁺
Years of Experience	of Top 20 Innovator Relationships	Years Average Partnership	CDMO Projects Executed
16	7	500 ⁺	14
CDMO Commercial Molecules	R&D Centres	Scientists	Manufacturing Sites
8	3500 ⁺ m ³		
USFDA / EDQM Accredited Sites	Reactor Capacity		



Achieved B-rating 2024 disclosure both in Climate Change & Water Security



Gold in Ecovadis Sustainability Assessment



Targets have been approved by SBTi



97% score in TFS audit



Pharmaceutical Supply Chain Initiative (PSCI) Supplier Partner- 2025



UN Global Compact Commitment for SDG Implementation



UN Global Women Empowerment Program (WEP)



Global Safety Accolade

Cohance Lifesciences: Our Integrated Global Manufacturing and Research Footprint



Small Molecule API CDMO

**CDMO Unit-I,
Suryapet**
Telangana, India



**API Unit-V,
Parwada**
Andhra Pradesh, India



**CDMO Unit-II,
Jeedimetla**
Telangana, India



**API R&D Unit-III,
Nacharam**
Telangana, India



**CDMO Unit-III,
Pashamylaram**
Telangana, India



**CDMO R&D Unit-I,
Genome Valley**
Telangana, India



**API Unit-IV,
Nacharam**
Telangana, India



ADCs

API Unit-IV, Nacharam
Telangana, India

API R&D Unit-III, Nacharam
Telangana, India

NJ Bio Inc, Princeton
New Jersey, USA

Nucleic Acid Chemistry

Sapala Organics,
IDA Mallapur
Telangana, India

NJ Bio Inc,
New Jersey, USA

API Unit-IV, Nacharam
Telangana, India

● R&D/Early-Stage Manufacturing ● Late-Stage/Commercial Manufacturing ● USFDA audited site

Recent Investments

cGMP oligonucleotide facility at Nacharam, Hyderabad, India

Dedicated OEB-6 high-containment block at Nacharam, Hyderabad, India

cGMP bioconjugation suite expansion at Princeton, U.S.



